BRIEF published on 06/27/2024 at 07:05, 2 years 3 months ago SCHOTT Pharma Reports Robust Growth in Q2 of Fiscal Year 2024 Global Expansion Revenue Growth SCHOTT Pharma Q2 2024 High-value Solutions
BRIEF published on 06/27/2024 at 07:05, 2 years 3 months ago SCHOTT Pharma annonce une croissance robuste au deuxième trimestre de l'exercice 2024 SCHOTT Pharma Expansion Mondiale Solutions À Haute Valeur Ajoutée Hausse Des Revenus T2 2024
PRESS RELEASE published on 06/27/2024 at 07:00, 2 years 3 months ago SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024 SCHOTT Pharma reports 11% revenue growth in Q2 2024, reaffirms guidance for fiscal year. Focus on high-value solutions and expansion. Key figures and strategic developments outlined Financial Results Expansion Revenue Growth SCHOTT Pharma High-value Solutions
BRIEF published on 06/14/2024 at 13:03, 2 years 3 months ago SCHOTT Pharma Opens State-of-the-Art Production Facility in Hungary SCHOTT Pharma Pharmaceutical Trends Hungary Production Facility Glass Syringes
BRIEF published on 06/14/2024 at 13:03, 2 years 3 months ago SCHOTT Pharma ouvre une usine de production de pointe en Hongrie SCHOTT Pharma Usine Hongrie Seringues En Verre Tendances Pharmaceutiques
PRESS RELEASE published on 06/14/2024 at 12:58, 2 years 3 months ago Expanding prefillable glass syringe output: SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza, Hungary SCHOTT Pharma opens new production facility in Hungary, expanding prefillable glass syringe output to support pharma market growth and trends SCHOTT Pharma Pharma Industry Hungary Production Facility Prefillable Glass Syringes
BRIEF published on 05/14/2024 at 18:24, 2 years 4 months ago SCHOTT Pharma Reaffirms FY 24 Outlook, Anticipates Slower Growth in FY 25 Due to Reduced Syringe Demand Financial Results SCHOTT Pharma FY 24 Forecast FY 25 Growth Impact Syringe Demand Decrease
BRIEF published on 05/14/2024 at 18:24, 2 years 4 months ago SCHOTT Pharma réaffirme ses perspectives pour l’exercice 24 et prévoit un ralentissement de la croissance au cours de l’exercice 25 en raison de la réduction de la demande de seringues Résultats Financiers SCHOTT Pharma Prévisions Pour L'exercice 24 Impact Sur La Croissance Pour L’exercice 25 Diminution De La Demande En Seringues
PRESS RELEASE published on 05/14/2024 at 18:19, 2 years 4 months ago SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes SCHOTT Pharma confirms FY 24 outlook based on Q2 results; FY 25 impacted by slower growth from syringes. H1 24 revenues up 9% at constant currencies Revenue Growth SCHOTT Pharma Syringes FY 24 FY 25
BRIEF published on 05/14/2024 at 18:08, 2 years 4 months ago SCHOTT Pharma Anticipates Fiscal Year 2025 Impact Due to Slower Syringe Sales Revenue Growth EBITDA Margin SCHOTT Pharma Fiscal Year 2025 Syringe Demand
Published on 10/03/2026 at 02:35, 21 hours 30 minutes ago Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 13:50, 1 day 10 hours ago AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 11 hours ago Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 11 hours ago Alaska Energy Metals Appoints Independent Director, Thomas Benson
Published on 10/03/2026 at 15:45, 8 hours 20 minutes ago Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 1 day ago IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 1 day 3 hours ago EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 1 day 4 hours ago innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 19:00, 1 day 5 hours ago INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 10/02/2026 at 17:45, 1 day 6 hours ago Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 1 day 6 hours ago Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 1 day 6 hours ago Peugeot Invest - Déclaration du nombre d'actions et de droits de vote
Published on 10/02/2026 at 17:30, 1 day 6 hours ago Aéroports de Paris SA - Calendrier financier 2027
